DCAL — Dishman Carbogen Amcis Share Price
0.000.00%
Last trade - 00:00- IN₹31.91bn
- IN₹52.67bn
- IN₹26.16bn
- 36
- 57
- 80
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.56 | ||
| Price to Tang. Book | 2.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.22 | ||
| EV to EBITDA | 15.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.06% | ||
| Return on Equity | -1.91% | ||
| Operating Margin | 3.23% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 20,436 | 19,120.3 | 21,406.9 | 24,129.2 | 26,157.7 | 29,839 | n/a | 4.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -8.5 | n/a | n/a | -56.35 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Company’s segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Directors
- Janmejay Vyas CHM
- Mark Griffiths CEO
- Arpit Vyas CFO
- Shrima Dave CCO
- Deohooti Vyas EDR (61)
- Maitri Mehta IND
- Subir Das NID
- Ashok Gandhi NID (76)
- Sanjay Majumdar NID
- Rajendra Shah NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 17th, 2007
- Public Since
- September 21st, 2017
- No. of Shareholders
- 51,701
- No. of Employees
- 1,132
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 156,783,095
- Address
- Dishman Corporate House, AHMEDABAD, 380058
- Web
- https://www.carbogen-amcis.com/
- Phone
- +91 2717420100
- Auditors
- T R Chadha & Co LLP
Upcoming Events for DCAL
Q1 2026 Dishman Carbogen Amcis Ltd Earnings Release
Dishman Carbogen Amcis Ltd Annual Shareholders Meeting
Similar to DCAL
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Dishman Carbogen Amcis share price?
As of Today at 20:16 UTC, shares in Dishman Carbogen Amcis are trading at IN₹206.12. This share price information is delayed by 15 minutes.
How has the Dishman Carbogen Amcis share price performed this year?
Shares in Dishman Carbogen Amcis last closed at IN₹206.12 and the price had moved by -11.69% over the past 365 days. In terms of relative price strength the Dishman Carbogen Amcis share price has underperformed the S&P BSE 100 Index by -16.81% over the past year.
What are the analyst and broker recommendations for Dishman Carbogen Amcis?
The overall consensus recommendation for Dishman Carbogen Amcis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dishman Carbogen Amcis dividend yield?
Dishman Carbogen Amcis does not currently pay a dividend.
Does Dishman Carbogen Amcis pay a dividend?
Dishman Carbogen Amcis does not currently pay a dividend.
When does Dishman Carbogen Amcis next pay dividends?
Dishman Carbogen Amcis does not currently pay a dividend.
How do I buy Dishman Carbogen Amcis shares?
To buy shares in Dishman Carbogen Amcis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dishman Carbogen Amcis?
As of the previous close price of IN₹206.12, shares in Dishman Carbogen Amcis had a market capitalisation of IN₹31.91bn.
Where are Dishman Carbogen Amcis shares listed?
Here are the trading details for Dishman Carbogen Amcis:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: DCAL
What kind of share is Dishman Carbogen Amcis?
Based on an overall assessment of its quality, value and momentum Dishman Carbogen Amcis is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dishman Carbogen Amcis share price forecast for 2025?
The analyst consensus target price for shares in Dishman Carbogen Amcis is IN₹167.10. That is 18.93% below the last closing price of IN₹206.12.
Analysts covering Dishman Carbogen Amcis currently have a consensus Earnings Per Share (EPS) forecast of IN₹12.50 for the next financial year.
Find out moreWhat is the trend in the Dishman Carbogen Amcis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dishman Carbogen Amcis. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +21.13%.
As of the last closing price of IN₹206.12, shares in Dishman Carbogen Amcis were trading -3.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dishman Carbogen Amcis PE Ratio?
The Dishman Carbogen Amcis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹206.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dishman Carbogen Amcis?
Dishman Carbogen Amcis' management team is headed by:
- Janmejay Vyas - CHM
- Mark Griffiths - CEO
- Arpit Vyas - CFO
- Shrima Dave - CCO
- Deohooti Vyas - EDR
- Maitri Mehta - IND
- Subir Das - NID
- Ashok Gandhi - NID
- Sanjay Majumdar - NID
- Rajendra Shah - NID